Calendario›AMGN›Apremilast · APPRAISE

Apremilast · APPRAISE

Study to Evaluate the Real-World Effectiveness, Safety and Tolerability of Treatment With Apremilast in Psoriatic Arthritis Patients Followed in Canadian Routine Care (APPRAISE)

Ensayo de AMGEN INC en Arthritis, Psoriatic (del registro, en inglés).

Fase

no aplica

Estado

Completado

Participantes

102

previstos

Centros

19

Fin del objetivo primario

abr 2021

fecha real

Qué significa cada fase y cada estado.

Estudio observacional. Comenzó en jul 2018.

Qué mide

The rate of achieving Low Disease Activity (LDA) (del registro, en inglés) (hasta aproximadamente 1 año)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis will be a Canadian observational study utilizing a prospective cohort design. Patients with active psoriatic arthritis (PsA) for whom the treating physician has decided, prior to and independently of enrollment in the study, to initiate treatment with Otezla® will be considered for participation in the study. Patients will be enrolled from the practices of predominantly community rheumatologists and will be followed for 12 months from the time of initiation of treatment with Otezla® In line with the observational nature of the study, there will be no protocol imposed tests or assessments. However, recommended follow up visits will be at 4, 8 and 12 months. In addition, patients may be asked to voluntarily complete self-administered questionnaires. The 24-month assessment will be aimed to determine whether or not treatment with Otezla® has been maintained, and if not, to ascertain the reason for discontinuation and what new treatment was initiated following discontinuation of Otezla®

Más ensayos de AMGN

Todos los de AMGN, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT03608657), actualizada en jun 2024.